<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 21, 2000
VIROPHARMA INCORPORATED
-----------------------
(Exact name of issuer as specified in charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-021699 23-2789550
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
</TABLE>
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
Item 5 - Other Events.
As is more fully described in the attached press release that is
incorporated herein by reference, on August 21, 2000, ViroPharma Incorporated
announced that the Securities and Exchange Commission has declared its
Registration Statement on Form S-3 (File No. 333-37960) effective as of August
21, 2000, registering the resale of its 6% Subordinated Convertible Notes due
March 1, 2007 and of shares of its common stock issuable upon conversion thereof
by certain holders of the Notes, pursuant to the Registration Rights Agreement
that ViroPharma entered into when the Notes were issued.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated August 21,
2000
<PAGE>
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: August 21, 2000 By: /s/ Claude H. Nash
------------------
Claude H. Nash
President and Chief Executive Officer
<PAGE>
Index to Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Incorporated Press Release dated August 21, 2000
